1-CBZ-4-甲氨基哌啶 | 405057-75-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-CBZ-4-甲氨基哌啶
• 中文别名: 4-甲基氨基哌啶-1-羧酸苄酯
• 英文名称: benzyl 4-(methylamino)piperidine-1-carboxylate
• CAS: 405057-75-2
• 化学式: C₁₄H₂₀N₂O₂
• 分子量: 248.325
• InChiKey: UKMMXAXGJCWGTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：室温、干燥密封

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Cbz-4-methylaminopiperidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Cbz-4-methylaminopiperidine
CAS number: 405057-75-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H20N2O2
Molecular weight: 248.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-CBZ-4-甲氨基哌啶 在 palladium 10% on activated carbon 、 2-氯-1-甲基吡啶碘化物 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®

  摘要：

  beta-Lactamase inhibitors with a bicyclic urea core and a variety of heterocyclic side chains were prepared and evaluated as potential partners for combination with imipenem to overcome class A and C beta-lactamase mediated antibiotic resistance. The piperidine analog 3 (MK-7655) inhibited both class A and C beta-lactamases in vitro. It effectively restored imipenem's activity against imipenem-resistant Pseudomonas and Klebsiella strains at clinically achievable concentrations. A combination of MK-7655 and Primaxin (R) is currently in phase II clinical trials for the treatment of Gram-negative bacterial infections. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.101
• 作为产物：
  描述：

  1-Cbz-4-哌啶酮 、 盐酸甲胺 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 碳酸氢钠 作用下， 以 1,2-二氯乙烷 、 水 为溶剂， 以100%的产率得到1-CBZ-4-甲氨基哌啶
  参考文献：
  名称：

  [EN] BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS
  [FR] BIS-PYRIDYLPYRIDONES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE DE CONCENTRATION DE LA MÉLANINE

  摘要：

  这项发明提供了新型的双吡啶基吡啉酮，它们是黑素浓集激素受体1（MCHR1）的拮抗剂，包含它们的药物组合物，它们的制备方法，以及它们在治疗和治疗肥胖和/或糖尿病中的用途。

  公开号：

  WO2009076387A1

文献信息

• [EN] PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS<br/>[FR] DERIVES DE PYRIDINE ET LEUR UTILISATION COMME ANTAGONISTES DE L'UROTENSINE II
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2005030209A1

  公开（公告）日：2005-04-07

  The invention relates to novel pyridine derivatives of formula 1 and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and their use as neurohormonal antagonists, especially as urotensin II inhibitors.

  该发明涉及公式1的新型吡啶衍生物和相关化合物，以及它们作为药物组成物中的活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组成物，以及它们作为神经荷尔蒙拮抗剂的用途，特别是作为尿泉素II抑制剂。
• Chemical Compounds
  申请人：Brown Dearg

  公开号：US20080200460A1

  公开（公告）日：2008-08-21

  Compounds of formula (I): wherein: when X is NR 5 , Y is absent or is CH 2 ; when X is CH 2 , Y is absent, CH 2 , NR 6 , O, S, S(O) or S(O) 2 ; Z is a 5- or 6-membered heterocyclyl ring; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).

  式(I)的化合物： 其中： 当X为NR5时，Y为不存在或为CH2； 当X为CH2时，Y为不存在、CH2、NR6、O、S、S(O)或S(O)2； Z为5-或6-成员的杂环烷基环； 包括这些化合物的组合物，制备它们的方法以及它们在医学治疗中的应用（例如在温血动物中调节CCR5受体活性）。
• THIA(DIA)ZOLES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS
  申请人：MacDonald Gregor James

  公开号：US20100120860A1

  公开（公告）日：2010-05-13

  The present invention relates to [1-(benzyl)-piperidin-4-yl]-([1,3,4]thiadiazol-2-yl)-amine and [1-(benzyl)-piperidin-4-yl]-(thiazol-2-yl)-amine derivatives of formula (I) that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

  本发明涉及式(I)的[1-(苄基)-哌啶-4-基]-([1,3,4]噻二唑-2-基)-胺和[1-(苄基)-哌啶-4-基]-(噻唑-2-基)-胺衍生物，它们是快速解离的多巴胺2受体拮抗剂，制备这些化合物的方法，以及包含这些化合物作为活性成分的制药组合物。这些化合物可用作治疗或预防中枢神经系统疾病的药物，例如精神分裂症，通过产生抗精神病作用而不产生运动副作用。
• BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS
  申请人：Allen Scott

  公开号：US20110118261A1

  公开（公告）日：2011-05-19

  The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and/or diabetes.

  该发明提供了一种新型双吡啶基吡啶酮，它们是黑色素浓聚激素受体1（MCHR1）的拮抗剂，包含它们的制药组合物，制备它们的过程，以及它们在治疗和治疗肥胖症和/或糖尿病方面的用途。
• ACYLAMINOPIPERIDINE COMPOUND
  申请人：Kontani Toru

  公开号：US20090131666A1

  公开（公告）日：2009-05-21

  [Problem] To provide a compound which has an excellent activity to modulate the functions of CCR4 or TARC and/or MDC and can be used for the prevention and/or treatment of various inflammatory diseases, allergic diseases, autoimmune diseases and the like. [Means for Resolution] An acylaminopiperidine compound represented by the formula (I) or a pharmaceutically acceptable salt thereof. [Symbols in the formula represent the following meanings; A: a single bond or C 1 -C 6 alkylene, R 1 : phenyl which may be substituted, etc., R 2 : —H or C 1 -C 6 alkyl, R 3 : —H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl, R 4 : pyrrolidin-2-yl which may be substituted, etc., and D: benzene ring or pyrazole ring].

  [问题] 提供一种化合物，该化合物具有优异的调节CCR4或TARC和/或MDC功能的活性，并可用于预防和/或治疗各种炎症性疾病、过敏性疾病、自身免疫性疾病等。 [解决方法] 一种由式(I)表示的酰胺哌啶化合物或其药学上可接受的盐。 [式中符号的含义如下：A：单键或C1-C6烷基，R1：可能被取代的苯基等，R2：-H或C1-C6烷基，R3：-H，C1-C6烷基或C3-C8环烷基，R4：可能被取代的吡咯烷-2-基等，D：苯环或吡唑环]。